More than chemotaxis: A new anti-tumor DC vaccine modified by rAAV2-SLC
文献类型：期刊论文
| 作者 | Liang, CM; Ye, SL; Zhong, CP; Zheng, N; Bian, W; Sun, RX; Chen, J; Li, RL; Zhou, S; Liu, YK |
| 刊名 | MOLECULAR IMMUNOLOGY
 |
| 出版日期 | 2007 |
| 卷号 | 44期号:15页码:3797-3804 |
| 关键词 | SLC rAAV2 BMDC PTX |
| 通讯作者 | Zhong, CP (reprint author), Fudan Univ, Shanghai Med Coll, Dept Anat & Histol & Embryol, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.,cpzhong@shmu.edu.cn |
| 英文摘要 | Secondary lymphoid tissue chemokine (SLC) is strongly expressed in secondary lymphoid organs. Its ability to facilitate chemotaxis of both dendritic cells (DC) and T cells makes it a promising candidate for cancer therapy. In this study, we modified a BMDC vaccine by incorporating the SLC mature peptide gene. The efficacy of this vaccine was evaluated using a mouse hepatocellular carcinoma (HCC) model, with rAAV2 as the gene delivery vector. The rAAV2 encoding SLC (rAAV2-SLC) transfected immature BMDCs at high efficiency and the anti-tumor effects of SLC gene modified BMDCs (rAAV2-SLC/BMDC) were evaluated. In addition, rAAV2-SLC/BMDC vaccine injected directly into tumors attracted more CD4(+) and CD8(+) T lymphocytes into tumors and showed stronger anti-tumor effects than footpad delivery. Moreover, we found that the phenotypic expression of MHC 11, the secretion of IL-12 and IFN-gamma, and T cell stimulation were increased in vitro following treatment with rAAV2-SLC/BMDC vaccine and these responses were inhibited by PTX. In vivo, PTX also inhibited the anti-tumor effects of the vaccine. The results suggest that the expression of SLC by rAAV2-SLC/BMDC plays more than a chemotactic role in anti-tumor responses, thus these studies further demonstrate that SLC has potential to be valuable in cancer therapy. (C) 2007 Elsevier Ltd. All rights reserved. |
| 学科主题 | Biochemistry & Molecular Biology; Immunology |
| 类目[WOS] | Biochemistry & Molecular Biology ; Immunology |
| 关键词[WOS] | LYMPHOID-TISSUE CHEMOKINE ; HIGH ENDOTHELIAL VENULES ; DENDRITIC CELLS ; ADENOASSOCIATED VIRUS ; CC-CHEMOKINE ; GENE-THERAPY ; TUMOR-REGRESSION ; T-LYMPHOCYTES ; IN-VIVO ; IMMUNITY |
| 收录类别 | SCI |
| 语种 | 英语 |
| WOS记录号 | WOS:000247822600018 |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.143/handle/331003/1624]  |
| 专题 | 上海生化细胞研究所_上海生科院生化细胞研究所 |
| 推荐引用方式 GB/T 7714 | Liang, CM,Ye, SL,Zhong, CP,et al. More than chemotaxis: A new anti-tumor DC vaccine modified by rAAV2-SLC[J]. MOLECULAR IMMUNOLOGY,2007,44(15):3797-3804. |
| APA | Liang, CM.,Ye, SL.,Zhong, CP.,Zheng, N.,Bian, W.,...&Liu, YK.(2007).More than chemotaxis: A new anti-tumor DC vaccine modified by rAAV2-SLC.MOLECULAR IMMUNOLOGY,44(15),3797-3804. |
| MLA | Liang, CM,et al."More than chemotaxis: A new anti-tumor DC vaccine modified by rAAV2-SLC".MOLECULAR IMMUNOLOGY 44.15(2007):3797-3804. |
入库方式： OAI收割
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。